





# PHARMACEUTICAL 2020

## LIXTE BIOTECHNOLOGY HOLDINGS INC. Rank 298 of 362

The relative strengths and weaknesses of LIXTE BIOTECHNOLOGY HOLDINGS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of LIXTE BIOTECHNOLOGY HOLDINGS INC. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 215% points. The greatest weakness of LIXTE BIOTECHNOLOGY HOLDINGS INC. is the variable Net Income, reducing the Economic Capital Ratio by 317% points.

The company's Economic Capital Ratio, given in the ranking table, is -497%, being 194% points below the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	2,672
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	238
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	50
Property and Equipment	0
Research and Development	821
Revenues	0
Selling, General and Administrative Expense	1,669

Output Variable	Value in 1000 USD
Assets	2,672
Liabilities	238
Expenses	2,490
Stockholders Equity	2,434
Net Income	-2,440
Comprehensive Net Income	-2,440
Economic Capital Ratio	-497%

